Wedbush Has Negative Forecast for Pharvaris FY2029 Earnings

Pharvaris (NASDAQ:PHVS) – Equities researchers at Wedbush dropped their FY2029 earnings estimates for Pharvaris in a research note issued on Wednesday, May 14th. Wedbush analyst L. Chico now expects that the company will post earnings per share of $5.51 for the year, down from their prior forecast of $5.99. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

A number of other research analysts also recently weighed in on the stock. Cantor Fitzgerald decreased their target price on shares of Pharvaris from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday. JMP Securities raised their target price on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research report on Friday, January 31st.

Pharvaris Trading Up 4.1%

Pharvaris stock opened at $16.56 on Thursday. The company has a market cap of $865.92 million, a P/E ratio of -5.91 and a beta of -2.85. Pharvaris has a 1-year low of $11.51 and a 1-year high of $25.50. The company has a fifty day simple moving average of $15.38 and a 200 day simple moving average of $17.68.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.09).

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PHVS. Deutsche Bank AG grew its position in shares of Pharvaris by 55.1% in the 1st quarter. Deutsche Bank AG now owns 28,174 shares of the company’s stock valued at $442,000 after acquiring an additional 10,006 shares during the period. TD Asset Management Inc grew its position in shares of Pharvaris by 41.5% in the 1st quarter. TD Asset Management Inc now owns 78,122 shares of the company’s stock valued at $1,227,000 after acquiring an additional 22,906 shares during the period. Palumbo Wealth Management LLC grew its position in shares of Pharvaris by 38.0% in the 1st quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company’s stock valued at $221,000 after acquiring an additional 3,881 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Pharvaris by 30.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company’s stock valued at $1,222,000 after acquiring an additional 14,838 shares during the period. Finally, Woodline Partners LP bought a new position in shares of Pharvaris in the 4th quarter valued at about $853,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.